On July 23, 2020, Inozyme Pharma, Inc., a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization, announced the pricing of its initial public offering of 7,000,000 shares of common stock at a public offering price of $16.00 per share, for gross proceeds of $112 million, before underwriting discounts and commissions and offering expenses payable by Inozyme. Additionally, the company has granted the underwriters a 30-day option to purchase up to 1,050,000 additional shares of common stock at the initial public offering price, less underwriting discounts and commissions.

Inozyme’s common stock began trading on the Nasdaq Global Select Market under the ticker symbol “INZY” on July 24, 2020.

The WilmerHale team advising Inozyme in its initial public offering was led by Brian Johnson, and included Caroline Dotolo, Andrea Sorrentino, and Meghan Muncey.